It looks like this message board has been pretty dead lately. Let's see if we can liven it up a bit.
A participant in another GLGC board asked about GLGC's Q1 conference call. A telephonic replay of the call will be available until tomorrow (May 13) at 800-633-8284 (U.S. and Canada) or +1 619-812-6440. When you call, enter reservation number 12314251. The replay will be available for several more months in the News & Events section of our Web site (www.genelogic.com).
Here are a few highlights from the call:
Review of Q1 events:
- We signed an agreement with Affymetrix Inc. to use their GeneChip(R) probe arrays in the development of the first of our GeneExpress(TM) databases. [Note: See our 1998 Annual Report, in print or on the Web, for a glossary of technical terms used in our industry.] We have already used GeneChip arrays to analyze gene expression in several hundred tissue samples and have produced excellent data.
- As we said on the Q4 call in March, we sold our OPM software to two additional companies in Q1.
- We commenced work on the new disease indications that are the subjects of our expanded agreements with the pharmaceutical divisions of Procter & Gamble and Japan Tobacco.
Outlook for new deals:
- There is more potential new business in our pipeline than at any other time in the company's history.
- We hope to have one or more new deals signed soon, but these will perhaps not come until the second half of the year. The deals are taking longer to negotiate than we previously anticipated because several new customers appear to be contemplating larger agreements than originally envisaged.
- We are still on schedule to launch the first GeneExpress database in the second half of 1999.
This message contains forward-looking information, including statements about prospective new customers, revenue growth, and sales of subscriptions to the GeneExpress databases. Such statements reflect management's current view of future events. Actual results may differ materially from these projections because of a number of factors, including risks related to competition, technological advances, technological challenges in developing genomic database products, the extent to which the pharmaceutical industry uses genomic information, market acceptance of the company's products (including the GeneExpress databases), the company's ability to enforce its intellectual property rights, and the impact of the intellectual property rights of others. There is no assurance that the company will be able to acquire new customers or retain current customers, that sales of subscriptions to the GeneExpress databases will occur in 1999 or at all, or that revenues will continue to grow. The success of the GeneExpress product line will depend in part on the ability of Affymetrix to supply adequate quantities of high-quality GeneChip arrays. These risk factors and others are more fully described in the company's Annual Report on Form 10-K for the year ended December 31, 1998, and other documents filed with the Securities and Exchange Commission
Steve Push
Vice President, Corporate Communications
Gene Logic Inc.
"Moving Drug Discovery into the Information Age" |
